Biolife Solutions Inc. (BLFS) is a leading developer, manufacturer and supplier of best-in-class cell and gene therapy bioproduction tools and services. Since its inception, this trailblazing company has been championing the development of innovative, proprietary solutions designed to increase the shelf life and improve the performance of biologic materials used in cell and gene therapies.
Headquartered in Bothell, Washington, Biolife Solutions has built a reputable name in the field of clinical grade biologic source material for cellular therapy applications. The uniqueness of BLFS lies in its focus on developing products that ensure optimal viability and function of biologic sources, key components that contribute significantly to the success of innovative new therapies.
BLFS's flagship product is CryoStor, a clinical grade freeze media, explicitly engineered to mitigate the cold-induced, apoptotic and necrotic damage pathways encountered by cells during the cryopreservation process. Their portfolio also includes HypoThermosol, a proprietary, optimized hypothermic storage and shipping media product, renowned for its capability in extending the shelf life of biologic source material.
One of the key strategic advances of Biolife Solutions is the acquisition of Astero Bio Corporation and SAVSU Technologies. These acquisitions have expanded BLFS's product offering to include novel thawing media and state-of-the-art cold storage and distribution products for cells, tissues, and organs.
Biolife Solutions, with its ongoing commitment towards research and development, continues its strategic collaborations with academic and industry thought leaders to bridge the gap between basic science and applied product development. These collaborations help the company to stay ahead of the curve and ensure an improved yield and extending viability of biologic source material.
In recent years, the company has significantly grown in numbers and reputation. Biolife Solutions has been supporting thousands of customers worldwide, ranging from large biopharma companies to small start-ups, and even academic research institutions, all striving to develop the next generation of cell and gene therapy breakthroughs.
In conclusion, Biolife Solutions Inc. (BLFS), with its robust line of biopreservation media products, state-of-the-art cold chain storage, and distribution solutions continues to be a critical ally for the rapidly emerging cell and gene therapy sector. The company's commitment to innovation and excellence rightly positions BLFS at the forefront of this exciting and potentially life-altering field.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Tidal Investments LLC has acquired 29,012 shares of BioLife Solutions, Inc. (NASDAQ:BLFS) valued at approximately $819,000, establishing a 0.06% stake in the company. Institutional investors now collectively own 93.24% of BioLife Solutions. The company recently reported strong quarterly results, exceeding analyst expectations for both revenue and EPS, though analysts maintain a "Hold" rating with a consensus price target of $31.38.
Squarepoint Ops LLC has acquired a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS), purchasing 132,942 shares valued at $3.75 million. This move comes as institutional investors now own 93.24% of the company, despite several analysts downgrading the stock to "Hold" or "Neutral" with revised price targets. BioLife Solutions recently surpassed earnings and revenue expectations, but its stock is trading near its 52-week high, with an average analyst target price of $31.38.
_07_03_2026_03_50_21_133108.jpg)
BioLife Solutions EVP and Chief Scientific Officer, Aby J. Mathew, withheld 627 common stock shares valued at $35.38 each on September 8, 2026, to cover tax obligations related to the release of restricted stock units (RSUs). This transaction, filed on a Form 4, indicates that Mathew directly holds 387,833 common stock shares after the withholding. The filing confirms that the transaction was for tax purposes and not executed under a Rule 10b5-1(c) trading plan.
BioLife Solutions (NASDAQ:BLFS) recently reached a new 52-week high of $38.10, with a market capitalization of $1.86 billion, despite analysts maintaining a "Hold" rating and an average price target of $31.38. The company reported a significant earnings beat of $0.91 per share against an estimate of $0.03, with revenues of $28.47 million. Institutional investors hold a substantial 93.24% of the stock, with the California State Teachers’ Retirement System notably increasing its position.
Ranger Investment Management L.P. acquired a new position of 238,521 shares in BioLife Solutions, Inc. (NASDAQ:BLFS) valued at approximately $6.7 million during the second quarter, representing 0.49% of the company's stock. Other institutional investors also adjusted their holdings, contributing to institutional ownership of 93.24%. Despite opening near its 52-week high, BioLife Solutions holds a consensus "Hold" rating from analysts with an average price target of $31.38, following several recent downgrades.